The inside story on US health care reform from law firm

10 September 2009

With a bevy of legislation is flooding the USA's Capitol Hill on health care reform, President Barrack Obama's speech on September 9 kicked debate on these initiatives into high gear. Eric Zimmerman, a partner in the Health Law Department of leading US law firm McDermott Will & Emery, weighed in on explaining the issues:

Q: How will health care service providers be impacted by health care reform?

A: Health care reform legislation will impact health care service providers in many ways. In addition to across-the-board blunt-instrument reimbursement reductions, lawmakers are also looking to infuse new incentives into reform to shape service provider behaviors. For example, more emphasis will be placed on health care quality, and more federal program reimbursement will be linked to reporting and achieving quality objectives. Those providers that already have sophisticated quality data gathering and reporting mechanisms in place will be at an advantage. Those that have genuine quality improvement programs that utilize nationally recognized measures will be even better off.

Q: What are some of the key reimbursement issues at play?

A: Health care reform legislation will necessarily need to be financed at least in part on the backs of health care service providers. Congress is not going to be able to come up with astronomical sums to finance this simply by looking to insurers and pharmaceutical manufacturers. Congress will need to reduce payments to hospitals, physicians, labs, home health agencies, skilled nursing facilities, DME suppliers and others. Cuts will be across-the-board cuts as well as more targeted reimbursement reductions.

Q: How should health care service providers prepare for reform?

A: Service providers of all types should budget using conservative assumptions, and predicting little to no growth, and maybe even 2% to 5% reductions in federal program payments. Service providers of all types also should begin dedicating considerable resources to measuring and improving quality using nationally recognized quality measures.

Q: If Congress fails to enact health care reform, what becomes of the many expiring Medicare provisions?

A: Congress will need to address many expiring Medicare provisions through some legislative vehicle, if not through health reform. The current conventional wisdom is that Congress will advance a Medicare bill, if consensus evaporates on health care reform. However, the timing of the collapse of health care reform may make it difficult for Congress to advance Medicare-only legislation in 2009. As such, many of these expiring provisions may actually expire, at least for a little while.

Q: What are the practical implications of advancing reform legislation through a reconciliation process? What is the real effect/meaning of the Byrd rule?

A: There are many political implications to advancing legislation through a reconciliation process, but there also are many practical implications. Current Senate rules prohibit the Senate from advancing revenue neutral provisions in a reconciliation bill, which means all provisions must either spend or save federal dollars. Gone from the bill therefore would be many of the reform proposals, and many of the "goodies" that have encouraged health care providers to support reform proposals to this point.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology